Agoracom Blog

AGORACOM Small Cap 60: Valeo Pharma $ $VPHIF Discusses Health Canada Approval for Redesca™ and Redesca Hp™ $30 Million Forecasted Annual Peak Sales $ $ $ $

Posted by AGORACOM-JC at 12:14 PM on Thursday, January 14th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Commercial launch to impact first half 2021 revenue
  • $30 million forecasted annual peak sales
  • 8 years of proven in-market safety Internationally
  • Low molecular weight heparin increasingly used to prevent COVID-19 driven complications

“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.

Hub On AGORACOM / Corporate Profile

Tags: , , , , , , , , , , , ,

Comments are closed.